Protecting the 'Kind' Family: Delhi High Court Cancels Deceptively Similar 'UNKIND' Trademark

In a significant ruling for the pharmaceutical industry, the High Court of Delhi has ordered the removal of the trademark ‘UNKIND’ from the Register of Trade Marks. The judgment, delivered by Justice Tejas Karia, reinforces the protective shield around the established ‘KIND’ family of marks owned by Mankind Pharma Ltd., citing concerns over market confusion and the protection of long-standing brand reputation.

The Backdrop: A Battle Over Brand Identity

Mankind Pharma Ltd., a major player in the pharmaceutical sector since 1991, challenged the registration of the mark ‘UNKIND’ (Class 35), which was registered by Ram Kumar (M/s Dr. Kumars Pharmaceuticals). Mankind Pharma, holding rights to the ‘MANKIND’ mark since 1986 and an extensive family of trademarks ending in ‘KIND’, argued that the impugned mark was not only adopted without bona fide intent but also threatened to dilute their established goodwill. Despite efforts to serve the Respondent, the case proceeded ex parte as the Respondent failed to appear or contest the allegations.

Arguments from the Petitioner

Counsel for Mankind Pharma emphasized that the ‘KIND’ family of marks had become synonymous with their company’s medicinal and pharmaceutical preparations. Key points raised included: * Established Reputation: With an annual turnover in the thousands of crores, the ‘KIND’ family of marks carries immense market influence. * Lack of Use: The Petitioner argued the ‘UNKIND’ mark was liable for cancellation under Section 47(1)(a) and (b) of the Trade Marks Act for non-use. * Deceptive Similarity: The Petitioner asserted that the use of ‘UNKIND’ in a similar market would inevitably lead to consumer confusion and allow the Respondent to "springboard" off Mankind Pharma’s established reputation.

Legal Analysis: The Court’s Reasoning

The Court found that because the Respondent chose not to participate, the allegations of the Petitioner remained uncontroverted. Justice Karia observed that the ‘KIND’ suffix, while not inherently descriptive of pharmaceutical products, had acquired a secondary meaning through the Petitioner’s extensive and continuous usage.

The court distinguished this case by applying the principle that once a brand has acquired such strong recognition, even a slight variation in the prefix—while keeping the distinctive family name—is likely to deceive the public. The court held that the adoption of the mark was not bona fide and clearly aimed at encroaching upon the Petitioner’s goodwill.

Key Observations

The judgment underscores the importance of protecting established brands, with the court noting:

• "The word ‘KIND’ has no relation to sale of the Pharmaceutical products and the Petitioner having established its first user of the word ‘KIND’ in the pharmaceutical market is entitled to a higher protection."
• "Merely changing the first part of the Impugned Trade Mark and using the distinguishing family name or characteristic is likely to cause confusion in the market."
• "The Impugned Trade Mark has been adopted by Respondent No.1 dishonestly to trade upon the established goodwill and reputation of the Petitioner and to project itself to be associated with the Petitioner."

A Decisive Conclusion

The Delhi High Court allowed the rectification petition, directing the Registrar of Trade Marks to cancel the registration of ‘UNKIND’. This decision serves as a stern reminder to market participants that capitalizing on the success of established brands through deceptively similar naming conventions will not be tolerated. For intellectual property holders, the judgment provides a clear path to seeking remedies when brand identity is threatened by potential "springboarding" competitors.